Adjuvant Dendritic Cell Therapy in Stage IIIB/C Melanoma: The MIND-DC Randomized Phase III Trial

In this phase III clinical trial, 148 patients with resected stage IIIB/C melanoma were randomized to adjuvant treatment with natural dendritic cells (nDCs) or placebo. Active treatment consisted of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens.